The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer

Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemother...

Full description

Saved in:
Bibliographic Details
Published in:Breathe (Lausanne, Switzerland) Switzerland), 2024-10, Vol.20 (3), p.240044
Main Authors: Mayenga, Marie, Pedroso, Ana Rita, Ferreira, Marion, Gille, Thomas, Pereira Catarata, Maria Joana, Duchemann, Boris
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c306t-26ead8357d325bd3e70502b8277cca6b47d9ca5721c566f519a94862f18a5313
container_end_page
container_issue 3
container_start_page 240044
container_title Breathe (Lausanne, Switzerland)
container_volume 20
creator Mayenga, Marie
Pedroso, Ana Rita
Ferreira, Marion
Gille, Thomas
Pereira Catarata, Maria Joana
Duchemann, Boris
description Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
doi_str_mv 10.1183/20734735.0044-2024
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11555582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_023ef71ae9c940d1b698c0c827243f8c</doaj_id><sourcerecordid>3128815257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c306t-26ead8357d325bd3e70502b8277cca6b47d9ca5721c566f519a94862f18a5313</originalsourceid><addsrcrecordid>eNpVkU1r3DAQhkVoSZY0f6CHomMvTjT6sOReSln6EUjpZe9iLMtrb21pK9uB_PvI3SQkc5Bg9M4z4n0J-QjsGsCIG860kFqoa8akLDjj8oxs1maxdt-RDRhgRWmEuSBX03RguYTIMjgnF6JSQsoKNsTtOk-3nXd_f-PsqYGSzqnH4QtFOvaDn-YYPO0DDT5ic1juMczUdX6M_TguIc6dT3h8oLGlIYZpxGGgzudjWMKeOgzOpw_kfYvD5K-e7kuy-_F9t_1V3P35ebv9dlc4wcq54KXHxgilG8FV3QivmWK8Nlxr57CspW4qh0pzcKosWwUVVtKUvAWDSoC4JLcnbBPxYI-pHzE92Ii9_d-IaW8xzb0bvGVc-FYD-spVkjVQl5VxzOVVXIrWuMz6emIdl3r0jfNhTji8gb59CX1n9_HeAqhchmfC5ydCiv-W7KMd-2l1BrOTy2QFcGNAcaWzlJ-kLsVpSr592QPMrmHb57DtGrZdw85Dn17_8GXkOVrxCCoEpCI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128815257</pqid></control><display><type>article</type><title>The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer</title><source>PubMed Central (Open Access)</source><creator>Mayenga, Marie ; Pedroso, Ana Rita ; Ferreira, Marion ; Gille, Thomas ; Pereira Catarata, Maria Joana ; Duchemann, Boris</creator><creatorcontrib>Mayenga, Marie ; Pedroso, Ana Rita ; Ferreira, Marion ; Gille, Thomas ; Pereira Catarata, Maria Joana ; Duchemann, Boris</creatorcontrib><description>Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.</description><identifier>ISSN: 1810-6838</identifier><identifier>EISSN: 2073-4735</identifier><identifier>DOI: 10.1183/20734735.0044-2024</identifier><identifier>PMID: 39534491</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><ispartof>Breathe (Lausanne, Switzerland), 2024-10, Vol.20 (3), p.240044</ispartof><rights>Copyright ©ERS 2024.</rights><rights>Copyright ©ERS 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c306t-26ead8357d325bd3e70502b8277cca6b47d9ca5721c566f519a94862f18a5313</cites><orcidid>0000-0002-1577-6595 ; 0000-0003-0872-2983 ; 0000-0002-4748-2911 ; 0000-0001-6311-0256</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555582/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555582/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39534491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayenga, Marie</creatorcontrib><creatorcontrib>Pedroso, Ana Rita</creatorcontrib><creatorcontrib>Ferreira, Marion</creatorcontrib><creatorcontrib>Gille, Thomas</creatorcontrib><creatorcontrib>Pereira Catarata, Maria Joana</creatorcontrib><creatorcontrib>Duchemann, Boris</creatorcontrib><title>The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer</title><title>Breathe (Lausanne, Switzerland)</title><addtitle>Breathe (Sheff)</addtitle><description>Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.</description><issn>1810-6838</issn><issn>2073-4735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1r3DAQhkVoSZY0f6CHomMvTjT6sOReSln6EUjpZe9iLMtrb21pK9uB_PvI3SQkc5Bg9M4z4n0J-QjsGsCIG860kFqoa8akLDjj8oxs1maxdt-RDRhgRWmEuSBX03RguYTIMjgnF6JSQsoKNsTtOk-3nXd_f-PsqYGSzqnH4QtFOvaDn-YYPO0DDT5ic1juMczUdX6M_TguIc6dT3h8oLGlIYZpxGGgzudjWMKeOgzOpw_kfYvD5K-e7kuy-_F9t_1V3P35ebv9dlc4wcq54KXHxgilG8FV3QivmWK8Nlxr57CspW4qh0pzcKosWwUVVtKUvAWDSoC4JLcnbBPxYI-pHzE92Ii9_d-IaW8xzb0bvGVc-FYD-spVkjVQl5VxzOVVXIrWuMz6emIdl3r0jfNhTji8gb59CX1n9_HeAqhchmfC5ydCiv-W7KMd-2l1BrOTy2QFcGNAcaWzlJ-kLsVpSr592QPMrmHb57DtGrZdw85Dn17_8GXkOVrxCCoEpCI</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Mayenga, Marie</creator><creator>Pedroso, Ana Rita</creator><creator>Ferreira, Marion</creator><creator>Gille, Thomas</creator><creator>Pereira Catarata, Maria Joana</creator><creator>Duchemann, Boris</creator><general>European Respiratory Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1577-6595</orcidid><orcidid>https://orcid.org/0000-0003-0872-2983</orcidid><orcidid>https://orcid.org/0000-0002-4748-2911</orcidid><orcidid>https://orcid.org/0000-0001-6311-0256</orcidid></search><sort><creationdate>20241001</creationdate><title>The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer</title><author>Mayenga, Marie ; Pedroso, Ana Rita ; Ferreira, Marion ; Gille, Thomas ; Pereira Catarata, Maria Joana ; Duchemann, Boris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c306t-26ead8357d325bd3e70502b8277cca6b47d9ca5721c566f519a94862f18a5313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayenga, Marie</creatorcontrib><creatorcontrib>Pedroso, Ana Rita</creatorcontrib><creatorcontrib>Ferreira, Marion</creatorcontrib><creatorcontrib>Gille, Thomas</creatorcontrib><creatorcontrib>Pereira Catarata, Maria Joana</creatorcontrib><creatorcontrib>Duchemann, Boris</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Breathe (Lausanne, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayenga, Marie</au><au>Pedroso, Ana Rita</au><au>Ferreira, Marion</au><au>Gille, Thomas</au><au>Pereira Catarata, Maria Joana</au><au>Duchemann, Boris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer</atitle><jtitle>Breathe (Lausanne, Switzerland)</jtitle><addtitle>Breathe (Sheff)</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>20</volume><issue>3</issue><spage>240044</spage><pages>240044-</pages><issn>1810-6838</issn><eissn>2073-4735</eissn><abstract>Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>39534491</pmid><doi>10.1183/20734735.0044-2024</doi><orcidid>https://orcid.org/0000-0002-1577-6595</orcidid><orcidid>https://orcid.org/0000-0003-0872-2983</orcidid><orcidid>https://orcid.org/0000-0002-4748-2911</orcidid><orcidid>https://orcid.org/0000-0001-6311-0256</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1810-6838
ispartof Breathe (Lausanne, Switzerland), 2024-10, Vol.20 (3), p.240044
issn 1810-6838
2073-4735
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11555582
source PubMed Central (Open Access)
title The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A35%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20CheckMate%20816%20trial:%20a%20milestone%20in%20neoadjuvant%20chemoimmunotherapy%20of%20nonsmall%20cell%20lung%20cancer&rft.jtitle=Breathe%20(Lausanne,%20Switzerland)&rft.au=Mayenga,%20Marie&rft.date=2024-10-01&rft.volume=20&rft.issue=3&rft.spage=240044&rft.pages=240044-&rft.issn=1810-6838&rft.eissn=2073-4735&rft_id=info:doi/10.1183/20734735.0044-2024&rft_dat=%3Cproquest_doaj_%3E3128815257%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c306t-26ead8357d325bd3e70502b8277cca6b47d9ca5721c566f519a94862f18a5313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3128815257&rft_id=info:pmid/39534491&rfr_iscdi=true